https://mindmedicinelaw.com/briefing/psilocybin-regulation-and-use-in-oregon-current-status-20260824-35337The Psychedelic Journalen2026-08-24T22:04:11.149360+00:00Psilocybin Regulation and Use in Oregon: Current Statuspsilocybin legalization, Oregon psilocybin regulation, psychedelic therapy, psilocybin policy, therapeutic psilocybin, psilocybin community impact, psilocybin research, psilocybin risks, psilocybin integration services, Oregon Health Authorityhttps://mindmedicinelaw.com/briefing/psilocybin-s-clinical-viability-faces-critical-challenges-20260824-35182The Psychedelic Journalen2026-08-24T15:05:18.251321+00:00Psilocybin's Clinical Viability Faces Critical Challengespsilocybin clinical trials, psychedelic therapy, mental health treatment, FDA regulations, serotonin receptors, psychedelic industry, therapeutic potential, clinical efficacy, regulatory challenges, psilocybin riskshttps://mindmedicinelaw.com/briefing/mdma-n-acylethanolamines-patent-implications-for-ptsd-treatment-20260824-35183The Psychedelic Journalen2026-08-24T15:05:05.828975+00:00MDMA-N-Acylethanolamines Patent: Implications for PTSD TreatmentMDMA-N-Acylethanolamines, PTSD treatment, psychedelic therapies, patent application, clinical trials, psychedelic industryhttps://mindmedicinelaw.com/briefing/neurothera-clearmind-s-mdma-ptsd-treatment-ip-gains-momentum-20260824-35181The Psychedelic Journalen2026-08-24T15:04:14.893965+00:00NeuroThera-Clearmind's MDMA-PTSD Treatment IP Gains MomentumMDMA, PTSD treatment, NeuroThera, Clearmind, psychedelic research, federal support, clinical trials, N-acylethanolamines, psychedelic therapies, market dynamicshttps://mindmedicinelaw.com/briefing/missouri-s-first-ketamine-clinic-a-new-era-in-psychedelic-therapy-20260823-35067The Psychedelic Journalen2026-08-23T22:03:49.668329+00:00Missouri's First Ketamine Clinic: A New Era in Psychedelic Therapyketamine therapy, psychedelic treatments, Missouri clinic, mental health, psychedelic-assisted therapy, NMDA receptors, depression treatment, PTSD therapy, psychedelic research, ketamine clinichttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-in-treating-depression-a-new-review-20260822-34835The Psychedelic Journalen2026-08-23T15:04:19.843925+00:00Psilocybin's Potential in Treating Depression: A New Reviewpsilocybin, depression treatment, major depressive disorder, psychedelic therapy, treatment-resistant depression, clinical trials, neuroscience, public health, mental health, antidepressant responsehttps://mindmedicinelaw.com/briefing/psilocybin-s-differential-impact-on-autism-new-insights-20260822-34805The Psychedelic Journalen2026-08-23T15:04:10.800060+00:00Psilocybin's Differential Impact on Autism: New Insightspsilocybin, autism spectrum disorders, brain networks, functional connectivity, clinical trials, psychedelic research, neurodevelopmental conditions, therapeutic potential, resting-state fMRI, King's College Londonhttps://mindmedicinelaw.com/briefing/triptally-analyzing-psychedelic-therapy-costs-with-open-access-tool-20260821-35103The Psychedelic Journalen2026-08-24T15:04:28.346038+00:00TripTally: Analyzing Psychedelic Therapy Costs with Open-Access Toolpsychedelic therapy, TripTally, cost calculator, economic modeling, labor costs, FDA approval, healthcare integration, therapy delivery models, clinical trials, public healthhttps://mindmedicinelaw.com/briefing/federal-audit-criticizes-kansas-on-parity-compliance-20260821-34806The Psychedelic Journalen2026-08-23T15:04:43.755391+00:00Federal Audit Criticizes Kansas on Parity ComplianceKansas Medicaid, parity compliance, OIG audit, mental health access, psychedelic therapies, behavioral health services, Medicaid MCOs, federal parity laws, mental health policy, treatment barriershttps://mindmedicinelaw.com/briefing/psilocybin-user-outcomes-in-oregon-colorado-insights-implications-20260821-34917The Psychedelic Journalen2026-08-23T15:04:30.641937+00:00Psilocybin User Outcomes in Oregon & Colorado: Insights & Implicationspsilocybin outcomes, Oregon psilocybin, Colorado psychedelics, real-world psilocybin use, psychedelic policy, psilocybin effects, psilocybin risks, psilocybin research, psychedelic therapy, public health strategieshttps://mindmedicinelaw.com/briefing/reevaluating-psychedelic-trial-designs-challenges-and-solutions-20260820-35106The Psychedelic Journalen2026-08-24T15:04:41.418953+00:00Reevaluating Psychedelic Trial Designs: Challenges and Solutionspsychedelic trials, clinical trial design, pretreatment expectancy, double-blind procedure, causal identification, alternative trial designs, psychedelic therapy, research methodology, ethical considerationshttps://mindmedicinelaw.com/briefing/visuomotor-mismatch-eeg-responses-implications-for-neuroscience-20260820-34526The Psychedelic Journalen2026-08-23T15:05:29.958378+00:00Visuomotor Mismatch EEG Responses: Implications for Neurosciencevisuomotor mismatch, EEG responses, predictive coding, neuroscience research, clinical trials, human cortexhttps://mindmedicinelaw.com/briefing/60-hz-light-therapy-for-depression-phase-2-trial-insights-20260820-34539The Psychedelic Journalen2026-08-23T15:05:21.201283+00:0060-Hz Light Therapy for Depression: Phase 2 Trial Insights60-Hz light therapy, major depressive disorder, non-pharmacological treatment, clinical trials, neuroscience, mental health policy, flickering white light, depression treatment, neural oscillations, integrative mental healthhttps://mindmedicinelaw.com/briefing/insulin-resistance-and-depression-new-treatment-insights-20260820-34544The Psychedelic Journalen2026-08-23T15:05:10.238079+00:00Insulin Resistance and Depression: New Treatment Insightsinsulin resistance, major depressive disorder, metabolic dysfunction, treatment-resistant depression, precision medicine, obesity and depression, HPA axis dysfunction, inflammation and depression, insulin pathways, personalized medicinehttps://mindmedicinelaw.com/briefing/psychedelic-therapies-for-nevada-veterans-impacts-and-challenges-20260820-34606The Psychedelic Journalen2026-08-23T15:05:00.964237+00:00Psychedelic Therapies for Nevada Veterans: Impacts and Challengespsychedelics, Nevada veterans, mental health, PTSD treatment, psychedelic policy, clinical trials, first responders, psilocybin, MDMA therapy, veteran supporthttps://mindmedicinelaw.com/briefing/neuromodulation-s-role-in-treating-resistant-depression-20260820-34542The Psychedelic Journalen2026-08-23T15:04:52.139584+00:00Neuromodulation's Role in Treating Resistant Depressiontreatment-resistant depression, neuromodulation, electroconvulsive therapy, repetitive transcranial magnetic stimulation, intermittent theta-burst stimulation, vagus nerve stimulation, deep brain stimulation, clinical positioning framework, equitable access, multidisciplinary carehttps://mindmedicinelaw.com/briefing/inflammation-s-role-in-depression-insights-challenges-20260819-34857The Psychedelic Journalen2026-08-23T22:04:16.034060+00:00Inflammation's Role in Depression: Insights & Challengesinflammation, major depressive disorder, CRP levels, precision medicine, biomarker stratification, anti-inflammatory treatments, clinical trials, neurotransmission, blood-brain barrier, neuroplasticityhttps://mindmedicinelaw.com/briefing/challenges-in-ehr-based-risk-models-for-trd-across-health-systems-20260819-34547The Psychedelic Journalen2026-08-23T22:04:07.862572+00:00Challenges in EHR-Based Risk Models for TRD Across Health Systemstreatment-resistant depression, electronic health records, risk models, transportability, clinical heterogeneity, data biases, health systems, predictive modeling, EHR limitations, TRDhttps://mindmedicinelaw.com/briefing/advances-in-rtms-for-psychiatric-disorders-challenges-and-future-directions-20260819-34548The Psychedelic Journalen2026-08-23T22:03:59.926146+00:00Advances in rTMS for Psychiatric Disorders: Challenges and Future Directionsrepetitive transcranial magnetic stimulation, psychiatric disorders, clinical efficacy, standardized parameters, biomarkers, multicenter trials, neuro-navigation, personalized treatment, brain stimulation, mental healthhttps://mindmedicinelaw.com/briefing/dextromethorphan-bupropion-new-hope-for-mdd-treatment-20260819-34546The Psychedelic Journalen2026-08-23T15:05:39.943503+00:00Dextromethorphan-Bupropion: New Hope for MDD Treatmentdextromethorphan, bupropion, major depressive disorder, mouse model, preclinical study, multimodal therapy, neurotransmitter imbalance, clinical trials, NMDA receptor, neurotrophic supporthttps://mindmedicinelaw.com/briefing/psilocybin-use-in-older-adults-new-insights-and-implications-20260818-35075The Psychedelic Journalen2026-08-24T15:04:54.082654+00:00Psilocybin Use in Older Adults: New Insights and Implicationspsilocybin, older adults, psychedelic research, state-regulated services, mental health, end-of-life care, clinical trials, therapeutic interventions, safety, efficacyhttps://mindmedicinelaw.com/briefing/ketamine-and-esketamine-for-post-op-pain-in-gynecological-surgery-20260818-34864The Psychedelic Journalen2026-08-23T22:04:26.271229+00:00Ketamine and Esketamine for Post-Op Pain in Gynecological Surgeryketamine, esketamine, postoperative pain, gynecological surgery, opioid alternatives, perioperative analgesia, Cochrane review, pain management, clinical trials, subanaesthetic doseshttps://mindmedicinelaw.com/briefing/fanon-s-insights-on-psychedelics-for-racialized-therapy-20260815-34495The Psychedelic Journalen2026-08-23T22:04:35.007223+00:00Fanon's Insights on Psychedelics for Racialized Therapypsychedelic therapy, Frantz Fanon, racialized individuals, anti-colonial frameworks, systemic racism, MDMA-assisted therapy, cultural sensitivity, equitable treatment, psychedelic research, colonial traumahttps://mindmedicinelaw.com/briefing/psychologists-personal-mdma-use-influences-therapy-attitudes-20260813-34514The Psychedelic Journalen2026-08-23T22:04:43.925600+00:00Psychologists' Personal MDMA Use Influences Therapy AttitudesMDMA-assisted therapy, psychologists' attitudes, personal MDMA use, evidence-based education, mental health treatment, therapeutic biases, MDMA-AT risks, clinical objectivity, therapeutic integration, healthcare professional training